Kisspeptin-10 Side Effects: What Studies Report

What the published literature on kisspeptin-10 covers

Kisspeptin-10 (also written KP-10 or metastin 45-54) is a decapeptide fragment of kisspeptin that acts at the KISS1 receptor, and a chemical biology report described cross-linking a furan-modified kisspeptin-10 to the KISS receptor in order to characterise that peptide-receptor interaction (PMID 28714670). Because the molecule sits at the top of the reproductive hormone axis, most published experiments were designed to measure hormone output, fertility endpoints or cell signalling, not to catalogue harms.

That design choice matters for anyone reading about adverse events. Across the papers surveyed on this page, a dedicated repeat-dose toxicology evaluation appears only once: a study in which researchers gave KP-10 once daily by intravenous administration for 14 days in dogs (PMID 34126799). The remaining reports are mechanistic, in vitro, observational or efficacy-focused, and they do not carry the structured adverse-event tables — incidence counts, severity grades, withdrawal rates — that clinical safety summaries normally draw on.

Study Types Behind the Evidence: What Studies Report

Systemic Toxicology in Animals: What Studies Report

The single toxicology-framed entry in this set evaluated KP-10 (metastin 45-54) after once-daily intravenous administration for 14 days in dogs (PMID 34126799). That design — a defined species, a defined route, a defined dosing period — is the standard shape of a preclinical repeat-dose study, and it is the only place in this citation set where a toxicology endpoint was the stated purpose rather than a secondary observation. This page does not restate dose levels, organ-specific findings or no-observed-adverse-effect thresholds from that report, because those details sit outside what the verified record supports here.

Two rodent experiments used kisspeptin-10 as an intervention against chemically induced reproductive injury rather than as a test article under toxicity surveillance. In one, researchers reported that intraperitoneal kisspeptin-10 administration ameliorated sodium arsenite-induced reproductive toxicity in adult male mice (PMID 34897760). In another, the study reported an ameliorating effect of kisspeptin-10 on methotrexate-induced sperm damage and testicular oxidative stress in rats (PMID 29862548). Protective findings in injury models describe what a compound did against a specific insult; they are not adverse-event surveillance, and they do not establish how an otherwise healthy animal or person responds.

Vascular and Endothelial Signals: What Studies Report

The most direct unfavourable laboratory signal in this set came from cell work: researchers reported that kisspeptin-10 induced endothelial cellular senescence and impaired endothelial cell growth (PMID 24405415). Senescence describes cells that stop dividing while remaining metabolically active, and impaired growth describes reduced proliferation in culture.

Two cautions apply to reading that result. First, it is an in vitro observation; concentrations, exposure times and culture conditions in a dish do not map directly onto circulating exposure in an intact organism. Second, no study in this citation set followed that endothelial signal into an animal or human cardiovascular outcome, so the published record stops at the cellular level (PMID 24405415). The absence of follow-up is itself part of the picture and is reported here as a gap, not as reassurance.

Hormonal and Reproductive Endpoints: What Studies Report

Human-facing work with kisspeptin clusters in reproductive endocrinology. One paper discussed kisspeptin as a promising oocyte maturation trigger for in vitro fertilisation in humans (PMID 28393578), a setting where the endpoint of interest is oocyte maturation and cycle outcome rather than a tolerability profile. A separate clinical endocrinology study examined the effect of gonadotropin-inhibitory hormone on luteinising hormone secretion in humans (PMID 28186349), which places kisspeptin signalling inside a broader set of human experiments measuring pituitary hormone output.

Because kisspeptin-10 acts upstream of gonadotropin release, any hormonal shift it produces is on-target pharmacology rather than an off-target effect — but that distinction does not tell a reader whether such shifts were tolerated, since the publications cited here reported hormone and fertility endpoints rather than graded adverse-event listings (PMID 28393578, PMID 28186349).

Pregnancy-Associated Observations: What Studies Report

Two observational papers measured kisspeptin in pregnant populations. A preliminary study examined the association of kisspeptin-10 levels with abortus imminens, or threatened miscarriage (PMID 21847585). A later report examined the association between first-trimester serum kisspeptin level and antenatal complications (PMID 40663448).

Both measured the body's own circulating peptide and related it to clinical events. Neither administered kisspeptin-10, so neither can be read as describing a side effect of a given peptide; an association between a biomarker level and a pregnancy complication does not establish direction of causation (PMID 21847585, PMID 40663448). A separate animal study reported that a maternal high-fat diet impaired follicular development in offspring through the intraovarian kisspeptin/GPR54 system (PMID 30670046), implicating the signalling system in a developmental outcome without administering the peptide as a treatment.

Cell-Line and Tissue Findings: What Studies Report

Direction of effect in cell culture varied with the cell type studied. In an oncology-focused experiment, researchers reported that kisspeptin-10 inhibited the proliferation, migration and stemness of esophageal cancer cells via regulation of SIX1/Wnt/β-catenin signalling (PMID 40192612). In a neuroscience experiment, the study reported that kisspeptin-10 rescued cholinergic differentiated SH-SY5Y cells from α-synuclein-induced toxicity in vitro (PMID 35563582).

Read alongside the endothelial senescence finding (PMID 24405415), these results show that kisspeptin-10 suppressed growth in some cell populations and preserved viability in others. Suppression of proliferation can be framed as desirable in a tumour line and undesirable in a vascular line; the biology is the same, the interpretation depends on the tissue. No paper in this set reconciled those observations in a whole-organism model.

Where Structured Adverse-Event Data Are Absent

Stated plainly, the following are not present in the verified literature reviewed for this page:

• No human adverse-event frequency tables, severity grading or discontinuation rates for kisspeptin-10, including in the IVF trigger literature (PMID 28393578).
• No long-term human follow-up; the longest defined dosing period in this set was 14 days of once-daily intravenous administration in dogs (PMID 34126799).
• No published data on repeated self-administration outside research or clinical settings, and no comparison of routes beyond those described in the cited reports (PMID 34897760).
• No translation of the in vitro endothelial senescence signal into a measured cardiovascular outcome in animals or humans (PMID 24405415).
• No studies in this set examining use during pregnancy as an intervention; the pregnancy papers were observational measurements of endogenous peptide (PMID 40663448).

How Study Design Shapes the Word "Side Effect"

In a toxicology study, harms are sought systematically: animals are observed on a schedule, tissues are examined, and findings are attributed to the test article — the design used in the 14-day intravenous dog evaluation (PMID 34126799). In a cell study, "harm" is a change in a cellular parameter such as senescence or growth rate (PMID 24405415). In an observational pregnancy study, the measured variable is a circulating concentration that the investigators did not control (PMID 21847585). These three meanings are not interchangeable, and collapsing them into a single list of "side effects" overstates what has been measured.

Readers comparing sources may also encounter kisspeptin-10 described through its receptor pharmacology rather than its clinical profile, as in the cross-linking work that mapped a modified kisspeptin-10 to the KISS receptor (PMID 28714670). Mechanistic characterisation of binding says nothing about tolerability.

Educational Disclaimer

This page is for educational purposes only and is not medical advice; consult a licensed physician about any health decision, medication or research compound. Kisspeptin-10 described in these publications was handled in research or clinical-research settings, and nothing here describes personal use. The content summarises what the cited investigators reported and does not make a judgement about whether kisspeptin-10 is tolerable, appropriate or otherwise suitable for any individual.

References

• Safety Evaluation of KP-10 (Metastin 45-54) Following once Daily Intravenous Administration for 14 Days in Dog (International Journal of Toxicology, 2021)
• Kisspeptin-10 induces endothelial cellular senescence and impaired endothelial cell growth (Clinical Science, 2014)
• Kisspeptin as a promising oocyte maturation trigger for in vitro fertilisation in humans (Gynecological Endocrinology, 2017)
• Effect of gonadotropin-inhibitory hormone on luteinizing hormone secretion in humans (Clinical Endocrinology, 2017)
• Cross-Linking Furan-Modified Kisspeptin-10 to the KISS Receptor (ACS Chemical Biology, 2017)
• Intraperitoneal kisspeptin-10 administration ameliorates sodium arsenite-induced reproductive toxicity in adult male mice (Andrologia, 2022)
• Ameliorating effect of kisspeptin-10 on methotrexate-induced sperm damages and testicular oxidative stress in rats (Andrologia, 2018)
• Association of kisspeptin-10 levels with abortus imminens: a preliminary study (Archives of Gynecology and Obstetrics, 2012)
• The association between 1st trimester serum kisspeptin level and antenatal complications (Ceska Gynekologie, 2025)
• Kisspeptin 10 Inhibited the Proliferation, Migration, and Stemness of Esophageal Cancer Cells via Regulating the SIX1/Wnt/β-Catenin Signaling (Journal of Biochemical and Molecular Toxicology, 2025)
• Kisspeptin-10 Rescues Cholinergic Differentiated SHSY-5Y Cells from α-Synuclein-Induced Toxicity In Vitro (International Journal of Molecular Sciences, 2022)
• Maternal high-fat diet impairs follicular development of offspring through intraovarian kisspeptin/GPR54 system (Reproductive Biology and Endocrinology, 2019)